The In-vitro Diagnostics Market is expected to reach $130.1 billion by 2030, at a CAGR of 4.6% during the forecast period 2023–2030. The rising prevalence of chronic diseases coupled with the increasing geriatric population, rising prevalence of acute and chronic infectious diseases, increasing funding for research activities, growing awareness regarding early disease diagnosis, growing demand for point-of-care (POC) diagnostics and rapid diagnosis, rising healthcare expenditure, and increasing funding for research activities are the key factors driving the growth of the IVD market. In addition, emerging economies, an inclination toward personalized medicine, and advancements in genomics & proteomics are expected to offer significant growth opportunities in the market.
The prevalence of chronic diseases and conditions such as cancer, diabetes, arthritis, and heart diseases are on the rise globally. According to the WHO, 41 million people die from chronic diseases each year, accounting for around 74% of all deaths globally. Growth in the geriatric population and social behaviors such as tobacco and alcohol use, physical inactivity, and unhealthy diets are major factors driving a steady increase in the number of people suffering from chronic diseases. According to the International Diabetes Federation, the global prevalence of diabetes is expected to reach 11.3% of the global population in 2030 from 10.5% in 2021.
Most older adults are diagnosed with chronic diseases due to declining bodily functions and immunity. Aging is associated with progressive deterioration in the structure and functioning of organs. The elderly population is more prone to various chronic diseases. According to World Population Prospects, the population aged 65 and above is growing more rapidly than other age groups. In 2019, 703 million people were in the age group of 65 years and above globally, and this number is projected to double to 1.5 billion by 2050. This remarkable growth in the elderly population is driven by declining fertility rates and improvements in longevity.
Furthermore, non-communicable diseases (NCDs), such as cancer, cardiovascular disease, diabetes, and mental illness, are becoming more prevalent. NCDs currently account for 70% of all deaths globally, with the majority recorded in low- & middle-income countries. Thus, the overall scenario indicates that the rising prevalence of chronic diseases coupled with the increasing geriatric population will increase diagnostic testing, driving the growth of the IVD market.
Click here to: Get a Free Sample Copy of this report
Increasing Funding for Research Activities Drives the Global In Vitro Diagnostics Market
R&D activities in academic and government research institutes and pharmaceutical companies have increased significantly. The funding for these activities is mainly driven by rising healthcare concerns, the complexity of clinical research, and the failure of drugs in earlier-phase studies.
In the U.S., the Department of Defense (DOD), the National Institute of Health (NIH), the Department of Energy (DOE), and NASA account for most public R&D investments. In addition, Research America stated that medical and health R&D spending in the U.S. grew by 11.1% from 2019 to 2020, reaching USD 245.1 billion. Pharmaceutical, medical technology, biotechnology, and health IT companies are expected to account for the largest share of investments in medical and health R&D in the U.S. during the forecast period, mainly due to increased research activities and the high demand for drugs for treating chronic illnesses. Moreover, the WHO states that, in 2020, chronic diseases account for almost three-quarters of all deaths worldwide, with the number of people with diabetes set to increase 2.5-fold by the end of 2020.
Thus, increasing R&D activities and growth in funding support the development of new assays and kits intended for use in diagnostic applications, driving the growth of the global IVD market.
The Reagents & Kits Segment is Expected to register the Highest CAGR During the Forecast Period
Based on the offering, the reagents & kits segment is expected to register the fastest growth during the forecast period. Factors such as rising awareness of rapid POC tests and increasing use of IVD kits and reagents to diagnose diseases in less time and cost support market growth. In addition, the frequent use of assays & kits in the detection of various chronic diseases, commercial availability of a diverse range of reagents, and increasing demand for COVID-19 testing products are driving the growth of this segment.
The Molecular Diagnostics Segment is Expected to Dominate the Global IVD Market in 2023
Based on technology, in 2023, the molecular diagnostic segment is expected to account for the largest share of the market. The segment’s large share is mainly attributed to the increasing prevalence of infectious diseases, technological innovations of the systems, and high sensitivity to detect infectious agents. The molecular diagnostics segment is further divided into polymerase chain reaction (PCR), hybridization, isothermal nucleic acid amplification technology, DNA sequencing & Next-generation sequencing, microarray, mass spectrometry, and other molecular diagnostic technologies.
Based on Application, the Infectious Disease Segment is Expected to Dominate the Global IVD Market in 2023
The large market share of this segment is mainly attributed to the high prevalence of infectious diseases, the rising geriatric population, the growing demand for early disease diagnosis, and government efforts to improve the accessibility of diagnostic services toward infectious disease testing. In vitro diagnostics (IVD) is the most popular diagnostic tool that meets the required standards. IVD kits are widely accepted and effective in diagnosing infectious diseases.
The OTC/Self-testing Segment is Expected to Register the Highest CAGR During the Forecast Period
OTC kits are generally at-home testing covering fertility testing, blood glucose monitoring, cholesterol testing, and infectious & chronic diseases testing. With home testing kits, patients can save time and money required for hospital/lab visits, as these tests can be performed at home, and results can be shared with physicians remotely. The large share of this segment can be attributed to the high demand for at-home testing and the high prevalence of diseases that require rapid and effective testing.
In 2023, the Diagnostic Laboratories Segment is Expected to Account for the Largest Share of the In Vitro Diagnostics Market
The large market share of this segment is primarily attributed to the rising laboratory automation, availability of well-equipped systems, high prevalence of infectious diseases, and presence of supportive government initiatives. Diagnostic laboratories are healthcare facilities that provide testing services to hospitals, clinics, and other healthcare institutes. Diagnostic laboratories process more samples in less time due to the well-equipped systems and the presence of skilled professionals, thereby accounting for the largest share of the market.
Asia Pacific: Fastest Growing Regional Market
North America is estimated to account for the largest share of the IVD market in 2023, while Asia Pacific is expected to grow at the fastest CAGR during the forecast period. The factors driving the growth of the Asia-Pacific IVD market are increasing investments by healthcare providers towards diagnostics infrastructure improvement, the growing burden of chronic and infectious diseases, the rising geriatric population, the growing accessibility to healthcare services, and the increasing number of hospitals & clinics.
Key Players
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years. The key players profiled in the global IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC (Argentina), QuidelOrtho Corporation (U.S.), Agilent Technologies Inc. (U.S.), and DiaSorin S.p.A. (Italy).
Scope of the Report:
In Vitro Diagnostics Market Assessment, by Offering
In Vitro Diagnostics Market Assessment, by Technology
In Vitro Diagnostics Market Assessment, by Application
In Vitro Diagnostics Market Assessment, by Diagnostic Approach
In Vitro Diagnostics Market Assessment, by End User
In Vitro Diagnostics Market Assessment, by Geography
Key questions answered in the report:
The global IVD market is segmented based on product & solution (reagents & kits, systems, and software & services) and a wide range of technologies (molecular diagnostics, point of care (POC), immunoassay/immunochemistry, biochemistry/clinical chemistry, whole blood glucose monitoring, microbiology, hematology, coagulation/hemostasis, urinalysis, and other IVD technologies) offered by key companies to various end users, such as diagnostic laboratories, hospitals & clinics, home healthcare, and other end users. The global IVD market studied in this report involves the value analysis of various segments and sub-segments of In Vitro diagnostics at regional and country levels.
The global IVD market is projected to reach $130.1 billion by 2030, at a CAGR of 4.6% during the forecast period.
The reagents & kits segment is expected to account for the largest share of the global IVD market in 2023. Factors such as the high burden of diseases, the high adoption of rapid diagnostic test kits, and the presence of initiatives supporting early disease diagnosis support the largest share of the segment.
Based on the technology, the molecular diagnostics segment is projected to create more traction.
Based on application, the cardiology segment is projected to register the highest growth during the forecast period due to the growing cardiovascular disease (CVD) burden and increasing research on cardiac biomarkers.
Based on end user, the hospitals & clinics segment is projected to register the highest growth during the forecast period due to many hospitalizations due to various diseases, the rising geriatric population, increasing healthcare access & expenditure, and the rising prevalence of healthcare-associated Infections (HAIs).
Rising prevalence of chronic and infectious diseases, growing awareness for early disease diagnosis, a shift in the focus from centralized to the point of care testing, and technological innovations. Further, emerging economies, the emergence of the COVID-19 pandemic, and advances in genomics and proteomics offer significant growth opportunities for the players operating in this market.
The key players operating in the global IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC (Argentina), QuidelOrtho Corporation (U.S.), Agilent Technologies Inc. (U.S.), and DiaSorin S.p.A. (Italy).
The emerging countries from Asia and Latin America are projected to offer significant growth opportunities for the vendors in this market due to rapid urbanization, increasing investments by healthcare providers towards infrastructure improvement, growing infectious diseases, and growing accessibility to healthcare services & advanced products.
This report provides pre & post COVID-19 market estimates.
1. Overview
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitation
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews With Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Market Share Analysis
2.3.3. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Rising Prevalence of Chronic Diseases Coupled With the Increasing Geriatric Population
4.2.2. Rising Prevalence of Infectious Diseases
4.2.3. Growing Demand for Point-of-Care (PoC) and Rapid Diagnostics
4.2.4. Rising Awareness Regarding Early Disease Diagnosis
4.2.5. Rising Healthcare Expenditures
4.2.6. Increasing Funding for Research Activities
4.3. Restraints
4.3.1. Stringent Technical Requirements and Regulatory Processes for High/Moderate-Complexity Tests
4.3.2. Variance in Test Results Observed in Rapid IVD Tests
4.4. Opportunities
4.4.1. Emerging Economies
4.4.2. Increasing Inclination Toward Personalized Medicine
4.4.3. Advancements in Genomics and Proteomics
4.5. Challenges
4.5.1. Evolving Regulatory Landscape
4.6. Technology Trends
4.6.1. Integration of Artificial Intelligence & Machine Learning in Molecular Diagnostics
4.6.2. Development of Smartphone-based Detection Platforms for Rapid Diagnostic Tests
4.6.3. Increasing Applications of Next-generation Sequencing Technology
5. In Vitro Diagnostics (IVD) Market: Regulatory Analysis
5.1. Overview
5.2. North America
5.2.1. U.S.
5.2.2. Canada
5.3. Europe
5.4. Asia-Pacific
5.4.1. China
5.4.2. Japan
5.4.3. India
5.5. Latin America
5.6. Middle East
6. In Vitro Diagnostics (IVD) Market Assessment—by Offering
6.1. Overview
6.2. Reagents & Kits
6.3. Systems
6.4. Software & Services
7. In Vitro Diagnostics (IVD) Market Assessment—by Technology
7.1. Overview
7.2. Molecular Diagnostics
7.2.1. Polymerase Chain Reaction (PCR)
7.2.2. Hybridization
7.2.3. Isothermal Nucleic Acid Amplification Technology
7.2.4. DNA Sequencing & Next-Generation Sequencing
7.2.5. Microarrays
7.2.6. Mass Spectrometry
7.2.7. Other Molecular Diagnostic Technologies
7.3. Point-of-Care (PoC) Diagnostics
7.3.1. Lateral Flow Assays/Rapid Tests
7.3.2. PoC Molecular Diagnostics
7.3.3. Other PoC Products
7.4. Immunoassay/Immunochemistry
7.4.1. Enzyme-linked Immunosorbent Assays (ELISA)
7.4.2. Enzyme-linked Immunospot Assays (ELISPOT)
7.4.3. Western Blotting
7.4.4. Radioimmunoassay
7.5. Biochemistry/Clinical Chemistry
7.5.1. Metabolic Panels
7.5.2. Electrolyte Panels
7.5.3. Liver Panels
7.5.4. Lipid Profiles
7.5.5. Renal Profiles
7.5.6. Thyroid Function Panels
7.6. Whole Blood Glucose Monitoring
7.7. Microbiology
7.8. Hematology
7.9. Coagulation/Hemostasis
7.10. Urinalysis
7.11. Other IVD Technologies
8. In Vitro Diagnostic (IVD) Market—by Application
8.1. Overview
8.2. Infectious Diseases
8.2.1. COVID-19 Testing
8.2.2. Sexually Transmitted Diseases (STD) Testing
8.2.3. Healthcare-associated Infections (HAIs)
8.2.4. Hepatitis
8.2.5. HIV
8.2.6. Tropical Diseases
8.2.7. Influenza
8.2.8. Respiratory Infections (Excluding Influenza)
8.2.9. Other Infectious Diseases
8.3. Oncology
8.4. Diabetes
8.5. Cardiology
8.6. Nephrology
8.7. Autoimmune Disorders
8.8. Other Applications
9. In Vitro Diagnostics (IVD) Market Assessment—by Diagnostic Approach
9.1. Overview
9.2. Laboratory Testing
9.3. OTC/Self Testing
9.4. Point-of-Care Testing
10. In Vitro Diagnostics (IVD) Market—by End User
10.1. Overview
10.2. Hospitals & Clinics
10.3. Diagnostic Laboratories
10.4. Home Healthcare
10.5. Other End Users
11. In Vitro Diagnostics (IVD) Market Assessment, by Geography
11.1. Overview
11.2. North America
11.2.1. U.S.
11.2.2. Canada
11.3. Europe
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Switzerland
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. South Korea
11.4.5. Australia
11.4.6. Rest of Asia-Pacific
11.5. Latin America
11.5.1. Brazil
11.5.2. Mexico
11.5.3. Argentina
11.5.4. Rest of Latin America
11.6. Middle East
11.6.1. Saudi Arabia
11.6.2. Rest of Middle East
11.7. Africa
11.7.1. South Africa
11.7.2. Rest of Africa
12. Competitive Landscape
12.1. Overview
12.2. Key Growth Strategies
12.3. Competitive Dashboard
12.3.1. Industry Leaders
12.3.2. Market Differentiators
12.3.3. Vanguards
12.3.4. Emerging Companies
12.4. Vendor Market Positioning
12.5. Market Share Analysis (2022: Top 15 Players)
12.5.1. F. Hoffman-La Roche Ltd. (Switzerland)
12.5.2. Abbott Laboratories (U.S.)
12.5.3. Danaher Corporation (U.S)
12.5.4. Siemens Healthineers AG (Germany)
12.5.5. Thermo Fisher Scientific Inc. (U.S.)
13. Company Profiles
13.1. Abbott Laboratories
13.2. Becton, Dickinson and Company
13.3. biomérieux S.A.
13.4. Danaher Corporation
13.5. F. Hoffman-La Roche Ltd
13.6. Qiagen N.V.
13.7. Siemens Healthineers AG (A Subsidiary of Siemens AG)
13.8. Thermo Fisher Scientific Inc.
13.9. Bio-Rad Laboratories, Inc.
13.10. Wama Diagnostica
13.11. lllumina, Inc.
13.12. Wiener Laboratories SAIC
13.13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
13.14. QuidelOrtho Corporation
13.15. Agilent Technologies, Inc.
13.16. DiaSorin S.p.A.
14. Appendix
14.1. Available Customization
14.2. Related Reports
List of Tables
Table 1 Global IVD Market: Impact Analysis of Market Drivers (2023–2030)
Table 2 Number of People With Diabetes Aged 20–79, by Region, 2021 Vs. 2030 Vs. 2045 (In Thousands)
Table 3 Population Aged 65 Years Or Above, by Region, 2019 Vs. 2030 Vs. 2050 (In Millions)
Table 4 Estimated Number of New Cancer Cases, by Type (2020 Vs. 2030)
Table 5 HIV Statistics (2021)
Table 6 Healthcare Expenditure As A Percentage of GDP, by Country (2014 Vs. 2019)
Table 7 Healthcare Expenditure, by Country (2020, 2021, and 2022)
Table 8 Global IVD Market: Impact Analysis of Market Restraints (2023–2030)
Table 9 Requirements for CLIA-Waived and Moderate/High-complexity PoC Molecular Diagnostic Tests
Table 10 Global IVD Market: Impact Analysis of Market Opportunities (2023–2030)
Table 11 Emerging Countries: Percentage of Urban Population (2021 Vs. 2025 Vs. 2050)
Table 12 Biomarkers and Corresponding Targeted Therapies Currently Available
Table 13 Clinical Applications of Genomics and Proteomics in Infectious Disease Diagnosis
Table 14 Global IVD Market: Impact Analysis of Market Challenges (2023–2030)
Table 15 Regulatory Authorities Governing In Vitro Diagnostics, by Country
Table 16 Some of the Emergency Use Authorizations (EUAs) Granted for IVD During the COVID-19 Pandemic
Table 17 Global In Vitro Diagnostics (IVD) Market, by Offering, 2021–2030 (USD Million)
Table 18 Global IVD Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 19 Global IVD Systems Market, by Country/Region, 2021–2030 (USD Million)
Table 20 Global IVD Software & Services Market, by Country/Region, 2021–2030 (USD Million)
Table 21 Global In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 22 Global Molecular Diagnostics Market, by Type, 2021–2030 (USD Million)
Table 23 Global Molecular Diagnostics Market, by Country/Region, 2021-2030 (USD Million)
Table 24 Key Companies Offering PCR Products
Table 25 Global Polymerase Chain Reaction Market, by Country/Region, 2021-2030 (USD Million)
Table 26 Global Hybridization Market, by Country/Region, 2021-2030 (USD Million)
Table 27 Key Companies Offering Isothermal Nucleic Acid Amplification Products
Table 28 Global Isothermal Nucleic Acid Amplification Market, by Country/Region, 2021–2030 (USD Million)
Table 29 Key Companies Offering DNA Sequencing & Next-generation Sequencing Products
Table 30 Global DNA Sequencing and Next-Generation Sequencing Market, by Country/Region, 2021-2030 (USD Million)
Table 31 Key Companies Offering Microarray Products
Table 32 Global Microarrays Market, by Country/Region, 2021–2030 (USD Million)
Table 33 Global Mass Spectrometry Market, by Country/Region, 2021-2030 (USD Million)
Table 34 Other Molecular Diagnostic Technologies Market, by Country/Region, 2021-2030 (USD Million)
Table 35 Global Point-of-Care (PoC) Diagnostics Market, by Technology, 2021-2030, (USD Million)
Table 36 Global Point-of-Care (PoC) Diagnostics Market, by Country/Region, 2021-2030, (USD Million)
Table 37 Global Lateral Flow Assays/Rapid Tests Market, by 2021-2030 (USD Million)
Table 38 Global PoC Molecular Diagnostics Market, 2021-2030 (USD Million)
Table 39 Other PoC Products Market, by Country/Region, 2021-2030 (USD Million)
Table 40 Global Immunoassay/Immunochemistry Market, by Type, 2021–2030 (USD Million)
Table 41 Global Immunoassay/Immunochemistry Market, by Country/Region, 2021–2030 (USD Million)
Table 42 Global Enzyme-Linked Immunosorbent Assays (ELISA) Market, by Country/Region, 2021–2030 (USD Million)
Table 43 ELISPOT Vs. Conventional ELISA
Table 44 Global Enzyme-Linked Immunospot Assays (ELISPOT) Market, by Country/Region, 2021–2030 (USD Million)
Table 45 Global Western Blotting Market, by Country/Region, 2021–2030 (USD Million)
Table 46 Global Radioimmunoassay Market, by Country/Region, 2021–2030 (USD Million)
Table 47 Global Biochemistry/Clinical Chemistry Market, by Type, 2021–2030 (USD Million)
Table 48 Global Metabolic Panels Market, by Country/Region, 2021–2030 (USD Million)
Table 49 Global Electrolyte Panels Market, by Country/Region, 2021-2030, (USD Million)
Table 50 Global Liver Panels Market, by Country/Region, 2021-2030, (USD Million)
Table 51 Global Lipid Profiles Market, by Country/Region, 2021-2030 (USD Million)
Table 52 Global Renal Profiles Market, by Country/Region, 2021-2030 (USD Million)
Table 53 Global Thyroid Function Panels Market, by Country/Region, 2021-2030 (USD Million)
Table 54 Number of People With Diabetes Aged 20–79 Years, by Region, 2019 Vs. 2030 Vs. 2045 (In Million)
Table 55 Global Whole Blood Glucose Monitoring Market, by Country/Region, 2021–2030 (USD Million)
Table 56 Key Companies Offering Microbiology-based IVD Products
Table 57 Global Microbiology Market, by Country/Region, 2021–2030 (USD Million)
Table 58 Key Companies Offering Hematology Products
Table 59 Global Hematology Market, by Country/Region, 2021–2030 (USD Million)
Table 60 Key Companies Offering Coagulation and Hemostasis Products
Table 61 Global Coagulation and Hemostasis Market, by Country/Region, 2021–2030 (USD Million)
Table 62 Key Companies Offering Urinalysis Products
Table 63 Global Urinalysis Market, by Country/Region, 2021–2030 (USD Million)
Table 64 Global Other IVD Technologies Market, by Country/Region, 2021–2030 (USD Million)
Table 65 Global In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 66 Global In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 67 Global In Vitro Diagnostics Market for Infectious Diseases, by Country/Region, 2021–2030 (USD Million)
Table 68 Recently Launched and Approved Rapid Diagnostic Tests for COVID-19 Detection
Table 69 Global Invitro Diagnostics Market for COVID-19 Testing, by Country/Region, 2021–2030 (USD Million)
Table 70 Global In Vitro Diagnostics Market for Sexually Transmitted Diseases (STD) Testing, by Country/Region, 2021–2030 (USD Million)
Table 71 Global In Vitro Diagnostics Market for Healthcare-associated Infections (HAIs), by Country/Region, 2021–2030 (USD Million)
Table 72 Global In Vitro Diagnostics Market for Hepatitis, by Country/Region, 2021–2030 (USD Million)
Table 73 Global Prevalence of HIV, by Region (2020)
Table 74 Global In Vitro Diagnostics Market for HIV, by Country/Region, 2021–2030 (USD Million)
Table 75 Global In Vitro Diagnostics Market for Tropical Diseases, by Country/Region, 2021–2030 (USD Million)
Table 76 Global In Vitro Diagnostics Market for Influenza, by Country/Region, 2021–2030 (USD Million)
Table 77 Global In Vitro Diagnostics Market for Respiratory Infections, by Country/Region, 2021–2030 (USD Million)
Table 78 Global In Vitro Diagnostics Market for Other Infectious Diseases, by Country/Region, 2021–2030 (USD Million)
Table 79 Global In Vitro Diagnostics Market for Oncology, by Country/Region, 2021–2030 (USD Million)
Table 80 Number of People With Diabetes Aged 20–79 Years, by Region, 2021 Vs. 2030 Vs. 2045 (In Million)
Table 81 Global In Vitro Diagnostics Market for Diabetes, by Country/Region, 2021–2030 (USD Million)
Table 82 Global In Vitro Diagnostics Market for Cardiology, by Country/Region, 2021–2030 (USD Million)
Table 83 Global In Vitro Diagnostics Market for Nephrology, by Country/Region, 2021–2030 (USD Million)
Table 84 Global In Vitro Diagnostics Market for Autoimmune Disorders, by Country/Region, 2021–2030 (USD Million)
Table 85 Global In Vitro Diagnostics Market for Other Applications, by Country/Region, 2021–2030 (USD Million)
Table 86 Global In Vitro Diagnostics Market, by Diagnostic Approach 2021-2030 (USD Million)
Table 87 Global In Vitro Diagnostics Market for Laboratory Testing, by Country/Region, 2021-2030 (USD Million)
Table 88 Global In Vitro Diagnostics Market for OTC/Self-testing, by Country/Region, 2021–2030 (USD Million)
Table 89 Global In Vitro Diagnostics Market for Point-of-Care Testing, by Country/Region, 2021–2030 (USD Million)
Table 90 Global In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 91 Global In Vitro Diagnostics Market for Hospitals & Clinics, by Country/Region, 2021-2030 (USD Million)
Table 92 Global In Vitro Diagnostics Market for Diagnostic Laboratories, by Country/Region, 2021-2030 (USD Million)
Table 93 Global In Vitro Diagnostics Market for Home Healthcare, by Country/Region, 2021-2030 (USD Million)
Table 94 Global In Vitro Diagnostics Market for Other End Users, by Country/Region, 2021-2030 (USD Million)
Table 95 Global In Vitro Diagnostics Market, by Country/Region, 2021 Vs. 2030 (USD Million)
Table 96 North America: In Vitro Diagnostics Market, by Country, 2021–2030 (USD Million)
Table 97 North America: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 98 North America: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 99 North America: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 100 North America: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 101 North America: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 102 North America: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 103 North America: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 104 North America: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 105 North America: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 106 North America: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 107 U.S.: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 108 U.S.: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 109 U.S.: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 110 U.S.: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 111 U.S.: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 112 U.S.: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 113 U.S.: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 114 U.S.: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 115 U.S.: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 116 U.S.: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 117 Canada: Prevalence of Diseases/Conditions in the Geriatric (Age 65 Years and Above) Population (2019–2020)
Table 118 Canada: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 119 Canada: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 120 Canada: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 121 Canada: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 122 Canada: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 123 Canada: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 124 Canada: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 125 Canada: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 126 Canada: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 127 Canada: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 128 Europe: In Vitro Diagnostics Market, by Country/Region, 2021–2030 (USD Million)
Table 129 Europe: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 130 Europe: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 131 Europe: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 132 Europe: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 133 Europe: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 134 Europe: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 135 Europe: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 136 Europe: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 137 Europe: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 138 Europe: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 139 Germany: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 140 Germany: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 141 Germany: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 142 Germany: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 143 Germany: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 144 Germany: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 145 Germany: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 146 Germany: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 147 Germany: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 148 Germany: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 149 France: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 150 France: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 151 France: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 152 France: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 153 France: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 154 France: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 155 France: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 156 France: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 157 France: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 158 France: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 159 U.K.: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 160 U.K.: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 161 U.K.: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 162 U.K.: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 163 U.K.: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 164 U.K.: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 165 U.K.: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 166 U.K.: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 167 U.K.: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 168 U.K.: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 169 Italy: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 170 Italy: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 171 Italy: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 172 Italy: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 173 Italy: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 174 Italy: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 175 Italy: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 176 Italy: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 177 Italy: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 178 Italy: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 179 Spain: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 180 Spain: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 181 Spain: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 182 Spain: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 183 Spain: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 184 Spain: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 185 Spain: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 186 Spain: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 187 Spain: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 188 Spain: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 189 Switzerland: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 190 Switzerland: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 191 Switzerland: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 192 Switzerland: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 193 Switzerland: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 194 Switzerland: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 195 Switzerland: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 196 Switzerland: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 197 Switzerland: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 198 Switzerland: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 199 Rest of Europe: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 200 Rest of Europe: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 201 Rest of Europe: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 202 Rest of Europe: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 203 Rest of Europe: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 204 Rest of Europe: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 205 Rest of Europe: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 206 Rest of Europe: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 207 Rest of Europe: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 208 Rest of Europe: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 209 Asia-Pacific: In Vitro Diagnostics Market, by Country/Region, 2021–2030 (USD Million)
Table 210 Asia-Pacific: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 211 Asia-Pacific: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 212 Asia-Pacific: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 213 Asia-Pacific: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 214 Asia-Pacific: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 215 Asia-Pacific: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 216 Asia-Pacific: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 217 Asia-Pacific: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 218 Asia-Pacific: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 219 Asia-Pacific: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 220 Japan: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 221 Japan: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 222 Japan: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 223 Japan: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 224 Japan: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 225 Japan: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 226 Japan: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 227 Japan: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 228 Japan: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 229 Japan: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 230 China: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 231 China: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 232 China: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 233 China: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 234 China: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 235 China: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 236 China: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 237 China: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 238 China: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 239 China: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 240 India: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 241 India: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 242 India: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 243 India: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 244 India: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 245 India: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 246 India: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 247 India: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 248 India: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 249 India: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 250 South Korea: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 251 South Korea: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 252 South Korea: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 253 South Korea: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 254 South Korea: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 255 South Korea: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 256 South Korea: In Vitro Diagnostics Market, by Application, 2021–2030
(USD Million)
Table 257 South Korea: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 258 South Korea: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 259 South Korea: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 260 Australia: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 261 Australia: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 262 Australia: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 263 Australia: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 264 Australia: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 265 Australia: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 266 Australia: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 267 Australia: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 268 Australia: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 269 Australia: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 270 Rest of Asia-Pacific: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 271 Rest of Asia-Pacific: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 272 Rest of Asia-Pacific: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 273 Rest of Asia-Pacific: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 274 Rest of Asia-Pacific: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 275 Rest of Asia-Pacific: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 276 Rest of Asia-Pacific: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 277 Rest of Asia-Pacific: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 278 Rest of Asia-Pacific: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 279 Rest of Asia-Pacific: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 280 Latin America: In Vitro Diagnostics Market, by Country, 2021–2030 (USD Million)
Table 281 Latin America: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 282 Latin America: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 283 Latin America: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 284 Latin America: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 285 Latin America: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 286 Latin America: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 287 Latin America: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 288 Latin America: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 289 Latin America: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 290 Latin America: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 291 Testing Initiatives for COVID-19 in Brazil
Table 292 Brazil: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 293 Brazil: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 294 Brazil: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 295 Brazil: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 296 Brazil: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 297 Brazil: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 298 Brazil: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 299 Brazil: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 300 Brazil: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 301 Brazil: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 302 Mexico: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 303 Mexico: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 304 Mexico: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 305 Mexico: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 306 Mexico: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 307 Mexico: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 308 Mexico: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 309 Mexico: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 310 Mexico: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 311 Mexico: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 312 Argentina: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 313 Argentina: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 314 Argentina: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 315 Argentina: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 316 Argentina: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 317 Argentina: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 318 Argentina: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 319 Argentina: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 320 Argentina: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 321 Argentina: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 322 Rest of Latin America: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 323 Rest of Latin America: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 324 Rest of Latin America: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 325 Rest of Latin America: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 326 Rest of Latin America: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 327 Rest of Latin America: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 328 Rest of Latin America: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 329 Rest of Latin America: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 330 Rest of Latin America: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 331 Rest of Latin America: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 332 Middle East: In Vitro Diagnostics Market, by Country, 2021–2030 (USD Million)
Table 333 Middle East: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 334 Middle East: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 335 Middle East: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 336 Middle East: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 337 Middle East: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 338 Middle East: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 339 Middle East: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 340 Middle East: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 341 Middle East: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 342 Middle East: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 343 Saudi Arabia: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 344 Saudi Arabia: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 345 Saudi Arabia: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 346 Saudi Arabia: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 347 Saudi Arabia: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 348 Saudi Arabia: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 349 Saudi Arabia: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 350 Saudi Arabia: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 351 Saudi Arabia: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 352 Saudi Arabia: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 353 Number of People Aged 65 Years and Above in the Middle East, 2017–2021 (In Thousands)
Table 354 Rest of Middle East: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 355 Rest of Middle East: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 356 Rest of Middle East: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 357 Rest of Middle East: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 358 Rest of Middle East: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 359 Rest of Middle East: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 360 Rest of Middle East: In Vitro Diagnostics Market, by Application, 2021–2030
(USD Million)
Table 361 Rest of Middle East: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 362 Rest of Middle East: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 363 Rest of Middle East: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 364 Africa: In Vitro Diagnostics Market, by Country/Region, 2021–2030 (USD Million)
Table 365 Africa: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 366 Africa: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 367 Africa: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 368 Africa: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 369 Africa: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 370 Africa: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 371 Africa: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 372 Africa: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 373 Africa: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 374 Africa: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 375 South Africa: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 376 South Africa: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 377 South Africa: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 378 South Africa: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 379 South Africa: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 380 South Africa: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 381 South Africa: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 382 South Africa: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 383 South Africa: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 384 South Africa: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 385 Rest of Africa: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 386 Rest of Africa: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 387 Rest of Africa: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 388 Rest of Africa: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
Table 389 Rest of Africa: In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2021–2030 (USD Million)
Table 390 Rest of Africa: In Vitro Diagnostics Market for Point-of-Care (PoC) Diagnostics, by Type, 2021–2030 (USD Million)
Table 391 Rest of Africa: In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 392 Rest of Africa: In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 393 Rest of Africa: In Vitro Diagnostics Market, by Diagnostics Approach, 2021–2030 (USD Million)
Table 394 Rest of Africa: In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 395 Recent Developments, by Company (2019-2023)
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation
Figure 7 Global In Vitro Diagnostics (IVD) Market, by Offering, 2023 Vs. 2030 (USD Million)
Figure 8 Global in Vitro Diagnostic (IVD) Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 9 Global in Vitro Diagnostic Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 10 Global in Vitro Diagnostic Market, by Diagnostic Approach, 2023 Vs. 2030 (USD Million)
Figure 11 Global in Vitro Diagnostic Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 12 Global IVD Market, by Geography
Figure 13 Factors Affecting Market Growth
Figure 14 U.S.: Medical and Health R&D Expenditure, 2016–2020 (USD Billion)
Figure 15 Global Biopharmaceutical R&D Expenditure, 2016–2028 (USD Billion)
Figure 16 USFDA Regulatory Pathways for IVD Kits
Figure 17 EU Regulatory Pathway - IVDR 2017/746
Figure 18 China: Medical Device Classification and Pre-Market Requirements for IVD Devices
Figure 19 Global In Vitro Diagnostics (IVD) Market, by Offering, 2023 Vs. 2030 (USD Million)
Figure 20 Global in Vitro Diagnostic Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 21 Global In Vitro Diagnostics Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 22 U.S.: Estimated Acute Hepatitis C Cases, 2011–2020
Figure 23 Estimated Number of New Cancer Cases, by Region, 2020–2040 (Million)
Figure 24 Total Number of Accredited Testing Laboratories (ISO/IEC 17025), 2016–2020
Figure 25 Prevalence of Diabetes Across the World (In Million)
Figure 26 Global In Vitro Diagnostics Market, by Diagnostic Approach 2023 Vs. 2030 (USD Million)
Figure 27 Benefits of Laboratory Testing Approach
Figure 28 Benefits of the Point-of-Care Testing Approach
Figure 29 Global In Vitro Diagnostics Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 30 Global In Vitro Diagnostics Market, by Region, 2023 Vs. 2030 (USD Million)
Figure 31 North America: Number of People Aged 65 Years and Above, 2015–2021 (Million)
Figure 32 North America: Per Capita Health Expenditure (USD), 2017–2021
Figure 33 North America: In Vitro Diagnostics Market Snapshot
Figure 34 Canada: Number of People Aged 65 and Above, 2018–2022 (Million)
Figure 35 Europe: Number of People Aged 65 and Above (In Million) (2015–2021)
Figure 36 Europe: In Vitro Diagnostics Market Snapshot
Figure 37 France: Percentage of Population Aged 65 Years and Above (2016–2021)
Figure 38 France: Prevalence of Chronic Diseases in People Aged 65 and Above (2020)
Figure 39 U.K: Number of Cancer Cases, 2010–2030 (Million)
Figure 40 U.K.: Number of Diabetes and Urogenital, Blood, and Endocrine Disease Cases – DALYS (Disability-Adjusted Life Years), 2017–2020 (Thousand)
Figure 41 U.K.: Number of People Diagnosed With Sexually Transmitted Infections, 2018–2020 (Thousand)
Figure 42 Prevalence of HAI in Healthcare-Associated Infections in Acute-Care Wards (2016–2021)
Figure 43 Italy: Ovarian Cancer Cases Diagnosed (2018–2020)
Figure 44 Number of HIV Tests Performed in Catalonia (Spain) (2014–2021)
Figure 45 Switzerland: Number of New Cancer Cases (2020–2040)
Figure 46 Switzerland: Number of People Aged 65 Years and Above (2017–2021)
Figure 47 Asia-Pacific: In Vitro Diagnostics Market Snapshot
Figure 48 Japan: Percentage Share of the Geriatric Population (Aged 65 Years And Above) (2015–2022)
Figure 49 Japan: New Cancer Cases Reported (2020–2040)
Figure 50 China: Independent Medical Laboratories Market, 2015–2021 (USD Million)
Figure 51 India: Number of People Aged 65 Years and Above, 2017–2021 (Million)
Figure 52 Latin America: In Vitro Diagnostics Market Snapshot
Figure 53 Brazil: Challenges To the In Vitro Diagnostics Market
Figure 54 Middle East: In Vitro Diagnostics Market Snapshot
Figure 55 Saudi Arabia: Number of People Aged 65 Years and Above, 2017–2021 (Thousand)
Figure 56 Africa: In Vitro Diagnostics Market Snapshot
Figure 57 South Africa: Number of People (All Ages) Living With HIV, 2010–2020 (Million)
Figure 58 South Africa: Number of People With Diabetes, 2000–2045 (Thousand)
Figure 59 Key Growth Strategies Adopted by Leading Players (2019–2023)
Figure 60 Competitive Dashboard: Global In Vitro Diagnostics Market
Figure 61 Global In Vitro Diagnostics Market Competitive Benchmarking, by Offering
Figure 62 Market Share Analysis: Global In Vitro Diagnostics Market (2022)
Figure 63 Abbott Laboratories: Financial Overview (2021)
Figure 64 Becton, Dickinson and Company: Financial Overview (2022)
Figure 65 biomérieux S.A.: Financial Overview (2021)
Figure 66 Danaher Corporation: Financial Overview (2021)
Figure 67 F. Hoffman-La Roche Ltd: Financial Overview (2021)
Figure 68 Qiagen N.V.: Financial Overview (2021)
Figure 69 Siemens Healthineers AG (A Subsidiary of Siemens AG): Financial Overview (2022)
Figure 70 Thermo Fisher Scientific Inc.: Financial Overview (2021)
Figure 71 Bio-Rad Laboratories: Financial Overview (2021)
Figure 72 Illumina, Inc.: Financial Overview (2021)
Figure 73 Shenzhen Mindray Bio-Medical Electronics Co., Ltd: Financial Overview (2021)
Figure 74 QuidelOrtho Corporation; Financial Overview (2021)
Figure 75 Agilent Technologies, Inc.: Financial Overview (2022)
Figure 76 DiaSorin S.p.A: Financial Overview (2021)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Feb-2023
Published Date: Sep-2022
Published Date: Sep-2022
